Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s...
-
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders...
-
Dublin, April 08, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Pharmacovigilance Market...
-
Deep Origin announced today that Tim Foley has joined the company as Chief Commercial Officer.
-
REDMOND, Wash., March 23, 2026 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced the publication of its latest...
-
REDMOND, Wash., March 18, 2026 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced expanded global intellectual property...
-
Deep Origin announced the promotion of Natalie Ma to Chief Business Officer. The company also welcomes Mostafa Ahmed as Senior Principal Scientist.
-
Organoid COMMONS appoints its Governing Board and Alliance Director. Member applications are open through April 30, 2026.
-
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.
-
Newly discovered drug leverages the power of Pattern Discovery Engine™ (PDE) and is an extension of 2025 study wherein Pattern developed novel risk assessment tool, discovered new drug target for...